175 related articles for article (PubMed ID: 15019062)
1. A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
Salas E; Ramírez A; Otero-Bilbao A; Vázquez R; Reyes O; Mendiola J; Duarte CA; Otero-González A; Gutiérrez OA; Chávez MA
J Pharm Biomed Anal; 2004 Mar; 34(4):833-40. PubMed ID: 15019062
[TBL] [Abstract][Full Text] [Related]
2. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
3. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
4. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
7. Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition.
Sharma A; Eapen A; Subbarao SK
J Biochem; 2004 Sep; 136(3):329-34. PubMed ID: 15598889
[TBL] [Abstract][Full Text] [Related]
8. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
9. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
10. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
12. Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target.
Ramírez AR; Guerra Y; Otero A; García B; Berry C; Mendiola J; Hernández-Zanui A; Chávez Mde L
Biotechnol Appl Biochem; 2009 Feb; 52(Pt 2):149-57. PubMed ID: 18471091
[TBL] [Abstract][Full Text] [Related]
13. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
14. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
15. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
Pranav Kumar SK; Kulkarni VM
Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
[TBL] [Abstract][Full Text] [Related]
17. Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic.
Kim YM; Lee MH; Piao TG; Lee JW; Kim JH; Lee S; Choi KM; Jiang JH; Kim TU; Park H
J Biochem; 2006 Feb; 139(2):189-95. PubMed ID: 16452306
[TBL] [Abstract][Full Text] [Related]
18. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
Silva AM; Lee AY; Gulnik SV; Maier P; Collins J; Bhat TN; Collins PJ; Cachau RE; Luker KE; Gluzman IY; Francis SE; Oksman A; Goldberg DE; Erickson JW
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10034-9. PubMed ID: 8816746
[TBL] [Abstract][Full Text] [Related]
19. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
[TBL] [Abstract][Full Text] [Related]
20. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
